Hologic (NASDAQ:HOLX) Price Target Raised to $85.00 at SVB Leerink

Hologic (NASDAQ:HOLXGet Rating) had its target price increased by SVB Leerink to $85.00 in a note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. SVB Leerink’s target price points to a potential upside of 8.28% from the company’s previous close.

Other analysts have also issued reports about the company. Morgan Stanley dropped their price objective on Hologic from $76.00 to $75.00 and set an “equal weight” rating on the stock in a report on Thursday, February 3rd. Citigroup dropped their price objective on Hologic from $78.00 to $75.00 in a report on Thursday, April 28th. Wells Fargo & Company lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $90.00 to $75.00 in a research note on Monday, April 25th. StockNews.com began coverage on Hologic in a research note on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, Raymond James lowered their price target on Hologic from $88.00 to $84.00 and set an “outperform” rating on the stock in a research note on Thursday, February 3rd. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $79.75.

HOLX stock traded up $1.28 during trading on Tuesday, hitting $78.50. 24,849 shares of the company traded hands, compared to its average volume of 2,079,472. The stock’s 50-day simple moving average is $74.77 and its 200 day simple moving average is $73.48. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.97 and a quick ratio of 2.57. The company has a market cap of $19.58 billion, a PE ratio of 12.97, a P/E/G ratio of 0.89 and a beta of 1.09. Hologic has a 1 year low of $60.10 and a 1 year high of $81.04.

Hologic (NASDAQ:HOLXGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.55 by $0.52. Hologic had a return on equity of 42.26% and a net margin of 28.79%. The company had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the company earned $2.59 earnings per share. Research analysts expect that Hologic will post 5.56 earnings per share for the current year.

In other Hologic news, insider Sean S. Daugherty sold 2,179 shares of the business’s stock in a transaction on Thursday, February 24th. The stock was sold at an average price of $71.14, for a total transaction of $155,014.06. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.54% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Delphia USA Inc. purchased a new stake in shares of Hologic in the 1st quarter valued at $397,000. Donoghue Forlines LLC raised its holdings in shares of Hologic by 54.3% in the 1st quarter. Donoghue Forlines LLC now owns 12,057 shares of the medical equipment provider’s stock valued at $926,000 after buying an additional 4,242 shares during the period. Earnest Partners LLC raised its holdings in shares of Hologic by 4.3% in the 1st quarter. Earnest Partners LLC now owns 984,669 shares of the medical equipment provider’s stock valued at $75,642,000 after buying an additional 40,774 shares during the period. Eaton Vance Management raised its holdings in shares of Hologic by 357.1% in the 1st quarter. Eaton Vance Management now owns 133,170 shares of the medical equipment provider’s stock valued at $10,230,000 after buying an additional 104,035 shares during the period. Finally, Ensign Peak Advisors Inc raised its holdings in shares of Hologic by 13.5% in the 1st quarter. Ensign Peak Advisors Inc now owns 247,192 shares of the medical equipment provider’s stock valued at $18,989,000 after buying an additional 29,365 shares during the period. Institutional investors own 92.70% of the company’s stock.

About Hologic (Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also

Stock Target Advisor logo

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.